Aesthetics: Solta prices $15M offering as acquisition charges, losses swell in 2nd quarter

Thu, 08/02/2012 - 5:34pm
Mass Device

Solta Medical prices a $15 million public offering to raise funds for general corporate purposes after the company incurs substantial charges tied to the $15 million acquisition of Liposonix.

Solta Medical logo

Solta Medical (NSDQ:SLTM) released pricing on a $15 million public offering intended to raise funds for general corporate purposes after the aesthetics devices maker incurred substantial charges during its 2nd quarter.

Solta's Q2 losses swelled more than 12600% on a $26 million "fair value reassessment" for fat-reduction device maker Liposonix, which the company acquired for $15 million plus pay-outs late last year. The new assessment doubles the previous consideration and brings the new total to $58.5 million in payments over the next 7 years.

The increase is "due primarily to our estimate of higher achievement in specified net sales and adjusted gross profit targets," Solta noted in its latest earnings report.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.